Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 1999

View Archived Issues

Crescendo submits two NDAs to FDA during Q3 1999

MGI Pharma makes significant progress with MGI-114 development during third quarter

Protease inhibitors for HCV infection developed at Vertex

Trademark verdict disputed by Pfizer

CDC advisory committee recommends Wyeth-Lederle's pneumococcal conjugate vaccine for routine use

Sheffield Pharmaceuticals completes inhaled steroid agreement with Elan

FP receptor agonists claimed by Procter & Gamble for bone disorders, glaucoma

New antitumor diterpenes discovered in China

Chinese researchers isolate new immunosuppressive fungal metabolite

PTPase inhibitors in early development at Novo Nordisk

Novel oncological compounds acting as antagonists of protein-carbohydrate binding

Merck's new GH secretagogues described in recent patent

Polyamine derivatives designed at U. of Florida for reduced toxicity

Patents cover Immtech's lead dicationic antifungal agents

Immtech receives patent coverage for rmCRP in platelet disorders

Agouron to commercialize Rescriptor throughout the world; anti-HIV pipeline grows

Development of OvaRex is now sole focus for AltaRex

Pharmacia & Upjohn reviews recent FDA developments for its products

Recent steps taken toward creation of Aventis

Antiepileptic potential of EPC-K1 demonstrated in rat model

LMW heparin to be marketed in U.K. and Ireland by ICN

First approval obtained for bivalirudin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...